Stockscreener 앱 받기
2.34
2.18%
0.05
시간 외 거래:
2.35
0.01
+0.43%
전일 마감가:
$2.29
열려 있는:
$2.28
하루 거래량:
745.78K
Relative Volume:
0.61
시가총액:
$422.03M
수익:
$109.16M
순이익/손실:
$-9.57M
주가수익비율:
-22.24
EPS:
-0.1052
순현금흐름:
$-104.72M
1주 성능:
+6.36%
1개월 성능:
+6.85%
6개월 성능:
+333.33%
1년 성능:
+341.51%
1일 변동 폭
$2.252
$2.36
1주일 범위
$2.19
$2.36
52주 변동 폭
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.34 | 413.01M | 109.16M | -9.57M | -104.72M | -0.1052 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock - Investing.com
SVP at Century Therapeutics (IPSC) sells shares to cover taxes - Stock Titan
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedViral Trade Signals - Newser
Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
H.C. Wainwright Increases Century Therapeutics Price Target to Five Dollars - HarianBasis.co
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC) - Insider Monkey
Century Therapeutics Selected for Oral Presentation of CNTY?813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Century Therapeutics to present diabetes therapy data at ADA - Investing.com
Century Therapeutics to present diabetes therapy data at ADA By Investing.com - Investing.com Canada
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Yahoo Finance
Century Therapeutics (NASDAQ: IPSC) sets 2026 virtual meeting and share authorization vote - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart.com
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading.Margin of Safety - UBND thành phố Hải Phòng
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
IPSC Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
H.C. Wainwright raises Century Therapeutics price target on diabetes therapy potential - Investing.com Canada
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat
[ARS] Century Therapeutics, Inc. SEC Filing - Stock Titan
Century Therapeutics (IPSC) seeks vote to add 150M shares, ratify EY - Stock Titan
Merger Talk: Will Century Therapeutics Inc benefit from seasonalityMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) awards 88,000 stock options to new director - Stock Titan
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan
CEO Moves: Will Century Therapeutics Inc benefit from current market trendsQuarterly Market Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Action: Is Century Therapeutics Inc undervalued by DCF analysisTake Profit & Expert Curated Trade Setups - baoquankhu1.vn
Panic Selling: What are the future prospects of Century Therapeutics IncBear Alert & Verified Momentum Watchlists - baoquankhu1.vn
Is Century Therapeutics (IPSC) Stock Attractive Now | Price at $2.26, Up 6.10%Stock Surge - Newser
Century Therapeutics (NASDAQ: IPSC) CSO has shares withheld for taxes - Stock Titan
IPSC Stock Analysis: Century Therapeutics Inc. biotech dips 2.74% to $2.13 in daily trading - Xã Vĩnh Công
IPSC Stock Analysis: Century Therapeutics Inc. 3.1% dip to $2.19 biotech performance review - Newser
IPSC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Options Flow: What are the future prospects of Century Therapeutics IncQuarterly Profit Summary & Smart Money Movement Tracker - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update - MarketBeat
VIX Spike: How does Century Therapeutics Inc perform in inflationary periods2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Century Therapeutics Updates ATM Program to Enhance Liquidity - TipRanks
Century Therapeutics updates equity offering program with $131.6 million remaining - Investing.com Australia
Century Therapeutics (IPSC) files $150M ATM shelf with TD Cowen - Stock Titan
Century Therapeutics (NASDAQ: IPSC) refreshes shelf and $150,000,000 ATM stock program - Stock Titan
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - MSN
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Century Therapeutics, Inc. has successfully sold common stock worth $18.4 million through investment bank TD Cowen. - Bitget
Weekly Trades: Is Century Therapeutics Inc in a bullish channel2026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Downgrade Watch: Will Century Therapeutics Inc benefit from seasonality2026 Dividend Review & Breakout Confirmation Alerts - baoquankhu1.vn
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Century Therapeutics reports 2025 results, advances cell therapy pipeline - MSN
Fed Meeting: Will Arch Capital Group Ltd outperform small cap indexes2026 Buyback Activity & Real-Time Volume Surge Alerts - baoquankhu1.vn
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):